ArticleASM case reports2025
Cefepime failure for the treatment of cefepime-susceptible, KPC-producing
Article in ASM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance.Journal of clinical microbiology · 2026Review
- From detection to decision: how laboratory testing and reporting strategies can shape management of carbapenemase-producingASM case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing incidence of carbapenem-resistant Enterobacterales (CRE) poses a challenge to clinical practice. Despite some Case Summary: Here, we present a case of clinical failure after cefepime treatment for a KPC-producing Conclusion: This case adds to the growing literature supporting the use of carbapenemase testing for Enterobacterales isolates that demonstrate resistance to one or more carbapenems to guide therapy. Until confirmatory clinical data are available, clinicians and laboratorians must consider selective reporting or other strategies in the setting of contradictory phenotypic susceptibility data and genotypic resistance markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.